Prof. Dr. Hasan Yazıcı
RheumatologyVerified
- 52+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Rheumatology
Stem cell transplant for scleroderma
What autologous stem cell transplant for scleroderma (AHSCT) is, how conditioning chemotherapy and stem cell infusion reboot the immune system, what major clinical trials show for severe systemic sclerosis, approximate treatment costs in Turkey compared with the UK, US and Germany, hospital stay duration, realistic recovery milestones, potential complications and questions to ask your medical team.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Rheumatology
- Hospitals
- 1
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Stem Cell Transplant for Scleroderma
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Stem cell transplant for scleroderma: what is it and how does it work?
A stem cell transplant for scleroderma—specifically autologous haematopoietic stem cell transplantation (AHSCT)—is an intensive medical procedure designed to halt the progression of severe, active systemic sclerosis. Unlike palliative symptom management, AHSCT aims to eliminate the malfunctioning immune cells responsible for autoimmune attack and rebuild a tolerant immune system from scratch. In this process, the patient's own blood-forming stem cells are harvested, stored, and then reinfused after high-dose chemotherapy has depleted the self-reactive lymphocyte population. For patients exploring international clinical pathways, haematology and rheumatology departments in Turkey provide these specialised cellular therapies within accredited hospital environments, as outlined in our overview of rheumatology treatments in Turkey.
It is essential to clarify what this therapy entails. AHSCT is not an aesthetic or outpatient regenerative procedure involving unproven adipose or umbilical stem cell injections. It is a major hospital-based haematological intervention requiring cytostatic conditioning, strict protective isolation, and multidisciplinary supervision. When considering stem cell transplant for scleroderma Turkey facilities, patients must distinguish regulated hospital transplants from informal cosmetic clinics.
Does a stem cell transplant for scleroderma actually work?
Clinical evidence from major international randomised trials—including the ASTIS, ASSIST, and SCOT trials—indicates that autologous haematopoietic stem cell transplantation provides substantial, long-term disease modification for select patients. In these landmark studies, patients undergoing AHSCT showed significant improvements in skin thickening, measured by the modified Rodnan skin score (mRSS), alongside stabilisation or partial recovery of forced vital capacity in interstitial lung disease. Long-term follow-up demonstrates higher event-free survival rates compared to standard monthly intravenous cyclophosphamide.
However, patients searching whether does stem cell transplant work for scleroderma must understand that transplant is not a universal cure. While it re-educates the adaptive immune repertoire, it cannot reverse extensive, established end-stage fibrotic scarring or permanently damaged internal organs. Skin flexibility and microvascular circulation often improve, but joint contractures that have already calcified or fused require ongoing physical therapy. Medical teams evaluate disease activity carefully to ensure the intervention halts active inflammation before irreversible damage occurs.
Who is an eligible candidate for AHSCT, and who is not?
Eligibility criteria for an autologous stem cell transplant for scleroderma are stringent because the conditioning regimen places substantial physiological stress on the body. Clinical guidelines from the European Society for Blood and Marrow Transplantation (EBMT) and the British Society for Rheumatology define candidates based on disease activity, duration, and organ reserve.
Suitable candidates typically present with:
- Rapidly progressive diffuse cutaneous systemic sclerosis with disease duration under four to five years.
- Documented active inflammation or worsening skin score despite standard immunosuppressive medications.
- Early internal organ involvement, such as active interstitial lung disease, without terminal fibrotic destruction.
- Sufficient organ reserve, confirmed by cardiac magnetic resonance imaging, echocardiogram, and pulmonary function testing.
Patients who are generally not eligible include those with:
- Severe, irreversible pulmonary arterial hypertension or left ventricular systolic dysfunction.
- Advanced pulmonary fibrosis with severely compromised gas exchange capacity.
- Significant renal failure, untreated chronic systemic infections, or severe frailty.
- Limited cutaneous systemic sclerosis without active, life-threatening internal organ progression.
Stem cell transplant for scleroderma cost in Turkey compared with the UK, US and Germany
Navigating treatment expenses for complex autoimmune therapies requires transparent clinical estimates. The overall stem cell transplant for scleroderma cost reflects multiple inpatient phases, including mobilisation medications, apheresis laboratory processing, stem cell cryopreservation, high-dose conditioning chemotherapy, supportive care in a positive-pressure HEPA isolation room, and post-transplant monitoring. The table below outlines broad approximate costs across key countries.
| Country | Approximate cost range |
|---|---|
| Turkey | €35,000 – €70,000 |
| United Kingdom | €80,000 – €160,000 |
| United States | €140,000 – €320,000 |
| Germany | €90,000 – €180,000 |
The final stem cell transplant for scleroderma price depends on pre-transplant diagnostic screening, the exact conditioning regimen (such as cyclophosphamide with antithymocyte globulin), the length of hospital isolation during the neutropenic phase, blood product transfusions, and post-engraftment follow-up. In Turkey, comprehensive treatment packages frequently include airport transfers, hospital accommodation, nursing care, and translator support, whereas Western private clinics often bill each phase separately. Before making financial commitments, international patients can request a comprehensive medical review and free quote based on their clinical records.
Autologous stem cell transplant compared with conventional immunosuppressive therapies
Rheumatologists evaluate multiple treatment tiers depending on whether disease progression is slow and manageable or rapid and refractory. While standard medical management relies on continuous medication to suppress immune function, AHSCT acts as a profound immune reset. Just as systemic autoimmune care differs in medication therapy for systemic lupus erythematosus, scleroderma requires tailored strategies matching disease aggressiveness.
| Therapy option | Best suited to | Typical limits |
|---|---|---|
| Autologous stem cell transplant (AHSCT) | Rapidly progressive diffuse cutaneous systemic sclerosis with high risk of organ failure | Involves intensive conditioning chemotherapy and an extended inpatient isolation period |
| Conventional immunosuppressants (e.g. cyclophosphamide, mycophenolate) | Slowly progressive disease, moderate skin involvement, maintenance therapy | May slow progression but often produces incomplete organ recovery or relapse on tapering |
| Targeted biologicals and antifibrotics (e.g. tocilizumab, nintedanib) | Scleroderma-associated interstitial lung disease or specific inflammatory flares | Controls lung fibrotic decline or joint inflammation without resetting the underlying immune system |
Neither therapy completely eliminates the risk of future flare-ups, but AHSCT has shown higher rates of medication-free remission in patients with diffuse, rapidly evolving systemic sclerosis. Your rheumatologist and haematologist will discuss whether the potential disease arrest outweighs the procedural demands.
The treatment stages: from stem cell mobilisation to reinfusion
Undergoing a stem cell transplant for scleroderma in Turkey involves a structured five-stage clinical pathway spanning several weeks in a specialized haematology centre:
- Pre-transplant comprehensive evaluation: Extensive cardiopulmonary assessment, including high-resolution chest computed tomography, echocardiography, right heart catheterisation if indicated, and baseline organ function checks.
- Mobilisation and harvesting: The patient receives granulocyte colony-stimulating factor (G-CSF), sometimes combined with low-dose chemotherapy, to stimulate stem cell release from the bone marrow into the peripheral bloodstream. A leukapheresis machine then separates and collects the CD34+ stem cells, which are cryopreserved.
- Conditioning (immunoablation): The patient enters a dedicated inpatient isolation unit. High-dose chemotherapy (typically cyclophosphamide, often paired with antithymocyte globulin or rabbit ATG) is administered over several days to eradicate the self-reactive immune system.
- Stem cell reinfusion ('Day Zero'): The cryopreserved autologous stem cells are thawed and infused through a central venous line, migrating to the bone marrow to initiate haematopoietic regeneration.
- Aplastic and engraftment phase: Over the subsequent 10 to 18 days, the patient experiences profound neutropenia and remains strictly protected from infection until new white blood cells, red cells, and platelets regenerate.
What before and after results can you realistically expect?
Understanding realistic clinical outcomes is vital when evaluating this therapy. In diffuse cutaneous systemic sclerosis, patients often experience significant softening of tightened, thickened skin over the first 6 to 12 months post-transplant, leading to improved facial mobility and hand function. Pulmonary function testing frequently reveals stabilisation of vital lung capacity, preventing the steep declines typically observed in untreated or refractory disease.
However, clinical results must not be confused with cosmetic transformations. AHSCT does not eliminate telangiectasias (spider veins) or established subcutaneous calcinosis deposits overnight. Patients with established flexion contractures in their fingers or elbows will retain joint limitations, although targeted rehabilitation often improves range of motion once skin tension relaxes. Honest medical discussions focus on halting progressive organ compromise and achieving long-term disease stabilization rather than complete physical restoration.
Inpatient stay and stem cell transplant for scleroderma recovery timeline
The stem cell transplant for scleroderma recovery journey requires patience, strict infection precautions, and continuous clinical oversight. Because the immune system takes months to mature, recovery occurs in progressive phases:
- Weeks 1 to 4 (Inpatient isolation): Spent in a specialised positive-pressure, HEPA-filtered haematology ward. During this aplastic phase, protective isolation prevents opportunistic infections while daily blood counts monitor marrow engraftment.
- Weeks 5 to 8 (Local recovery in Turkey): Once absolute neutrophil counts recover to safe levels and transfusion support is no longer needed, patients transition to outpatient accommodations near the hospital for regular blood testing and clinical reviews before cleared to travel home.
- Months 3 to 6 (Home recovery): Daily energy improves gradually. Patients remain on prophylactic antibiotics, antivirals, and antifungal medications, avoiding crowded environments, unpasteurised foods, and public exposure.
- Months 6 to 12 (Immune reconstitution): Blood counts and lymphocyte subsets steadily normalize. Skin softening becomes pronounced, and repeat pulmonary function scans evaluate organ stabilisation.
To ensure seamless travel and medical continuity during your overseas stay, patients can review how it works regarding transport, translation, and coordinated discharge planning.
What are the recognized risks and complications of AHSCT?
Autologous haematopoietic stem cell transplantation is an aggressive medical therapy with well-documented risks. Leading medical authorities, including the NHS, the European Society for Blood and Marrow Transplantation (EBMT), and the British Society for Rheumatology, emphasise that candidate selection must balance potential benefits against procedure-related complications.
Major recognised stem cell transplant for scleroderma risks include:
- Severe neutropenic infections: The temporary eradication of white blood cells leaves patients vulnerable to bacterial, fungal, and viral infections (such as cytomegalovirus reactivation).
- Cardiotoxicity: High-dose cyclophosphamide can induce transient myocardial dysfunction, arrhythmias, or pericardial effusion, which is why rigorous pre-transplant cardiac evaluation is non-negotiable.
- Prolonged cytopenias: Delayed platelet or red blood cell recovery may necessitate repeated transfusions.
- Treatment-related mortality: Historical clinical trials recorded a procedural mortality rate between 3% and 6%, largely attributed to infection or cardiac events. In modern specialised centres with enhanced cardiac screening protocols, treatment-related mortality has dropped significantly but remains a serious clinical consideration.
- Secondary autoimmune conditions: A small percentage of patients may develop secondary thyroid disorders or immune cytopenias years after transplant.
How to choose a transplant centre in Turkey and avoid dangerous red flags
Choosing a hospital for an autologous stem cell transplant requires strict due diligence. Cellular therapy must only be undertaken in licensed tertiary hospitals equipped with JACIE (Joint Accreditation Committee ISCT-Europe & EBMT) accreditation or national ministry of health bone marrow transplantation licensing. Accredited centres providing rheumatology treatments in Turkey maintain dedicated HEPA-filtered bone marrow units, 24-hour intensive care support, and joint rheumatology-haematology multidisciplinary boards.
Dangerous red flags to avoid:
- Clinics offering outpatient stem cell injections (such as adipose-derived or umbilical cord mesenchyme) claiming to cure scleroderma without chemotherapy.
- Facilities lacking on-site intensive care, blood transfusion services, or dedicated haematology isolation wards.
- Providers offering flat guarantees of cure or downplaying the risks of chemotherapy and immunosuppression.
- Quotes without detailed breakdowns of mobilisation, apheresis, isolation, and emergency contingency coverage.
To ensure safety and transparent logistics, prospective patients can examine how it works and submit clinical records for independent assessment via our secure free quote portal.
Essential questions to ask your haematology and rheumatology team
Before agreeing to undergo AHSCT, discuss these critical questions with your medical specialists:
- Is my scleroderma classified as rapidly progressive diffuse disease suitable for AHSCT under EBMT guidelines?
- Does your transplant centre hold JACIE accreditation or national haematology certification?
- How many scleroderma or autoimmune transplants has your clinical team performed?
- What conditioning chemotherapy regimen do you recommend for my cardiac and pulmonary status?
- What are your centre's specific infection control protocols during the aplastic isolation phase?
- What emergency intensive care support is immediately available if complications arise?
- What is the anticipated length of hospital isolation before I am safe to fly home?
- How will aftercare and immune reconstitution monitoring be coordinated with my rheumatologist at home?
Conditions treated with Stem Cell Transplant for Scleroderma
Hospitals with Rheumatology in Turkey
Frequently asked questions
It is an autologous haematopoietic stem cell transplantation (AHSCT) where a patient's own blood stem cells are harvested, high-dose conditioning chemotherapy clears self-reactive immune cells, and the stem cells are reinfused to reboot the immune system. It treats severe, rapidly progressing diffuse systemic sclerosis.
Yes, major clinical trials like ASTIS and SCOT demonstrate that AHSCT significantly improves skin thickness, stabilises lung function, and offers better event-free survival than conventional cyclophosphamide. It does not reverse end-stage fibrotic organ damage, which is why early intervention is critical.
Approximate costs in Turkey typically range between €35,000 and €70,000, depending on pre-transplant diagnostics, conditioning chemotherapy protocols, inpatient isolation length, and medication requirements. In comparison, treatment in the UK or Germany often exceeds €80,000 to €180,000.
Before and after outcomes typically show significant softening of tightened skin, improved mouth opening and hand mobility, and stabilized pulmonary function tests. It halts active disease progression, though it cannot reverse fixed joint contractures or preexisting severe internal organ scarring.
Initial recovery involves three to four weeks in hospital isolation until blood counts engraft. Patients spend another two to four weeks in local outpatient care before returning home. Full immune system reconstitution and energy recovery take roughly six to twelve months under medical supervision.
The stem cell reinfusion itself is painless, similar to a blood transfusion. However, the conditioning chemotherapy causes temporary fatigue, nausea, mouth ulcers, and hair loss. Supportive medications and protective isolation ensure symptoms remain controlled throughout the vulnerable aplastic phase.
Long-term clinical registry data show that many patients achieve sustained disease remission and skin softening lasting five to ten years or longer without ongoing immunosuppressive drugs. A minority may experience disease recurrence, requiring secondary medical management.
It is an aggressive treatment with recognized risks, including serious infection and cardiotoxicity during the neutropenic window. Modern protocols with strict cardiac screening have reduced treatment-related mortality, but it is reserved strictly for patients with active, life-threatening diffuse disease.
Conventional immunosuppressants like mycophenolate mofetil or cyclophosphamide slow disease progression but require continuous administration and rarely reverse skin tightness. AHSCT completely resets the immune repertoire, offering higher rates of long-term treatment-free disease stabilization in aggressive cases.
Patients generally stay between six and ten weeks in Turkey. This duration covers pre-transplant cardiac and pulmonary workups, stem cell harvesting, conditioning chemotherapy, three to four weeks in sterile hospital isolation, and post-engraftment outpatient observation before receiving clearance to travel.
Patient stories